Clinical Trial Update: Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of QVA149 in COPD completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2013-02-28